Blog - Page 3820 of 5699

MondayJun 07, 2010 10:53 am

ZymoGenetics, Inc. (ZGEN) Initiates Phase 2 Clinical Trial for Hepatitis C Investigational Drug Treatment

ZymoGenetics Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases such as hepatitis C, metastatic melanoma, psoriasis, diabetes, atopic dermatitis and more. The company has secured collaboration agreements with Bristol-Myers Squibb Company (NYSE: BMY), Bayer Schering Pharma AG and Merck Serono S.A. The company recently announced it has commenced the second part of a phase 2 clinical trial in collaboration with Bristol-Myers for investigational drug PEG-Interferon lambda (IL-29) and ribavirin in treatment-naïve patients with chronic hepatitis C virus infection. In a phase 1b clinical trial, PEG-Interferon was administered in…

MondayJun 07, 2010 10:26 am

Lorus Therapeutics (LRUSF.OB) Explains Preliminary Short Form Prospectus Filing

The bio-pharmaceutical company Lorus Therapeutics filed a preliminary short form in Canada. The short form covers the provinces of Ontario, Alberta, and British Columbia. The filing was done in connection to an offering of up to $17.5 million in units of the Company. Each unit consists of one common share of company stock and one-half of a warrant to purchase common shares. To explain the process a bit further, each whole warrant will permit the holder to purchase one common share at an initial exercise price of 125% of the unit being offered, priced at the time of sale. Subsequently…

MondayJun 07, 2010 10:10 am

Cyberonics, Inc. (CYBX) Posts Record Sales and Profits

Cyberonics recently announced their 4th quarter and fiscal year results. The medical technology company has been gaining traction with their novel Vagus Nerve Stimulation (VNS) Therapy System. Overall company sales totaled $167.8 million. The gross profit for the 4th Qtr of fiscal 2010 represented 88.5% of net sales, compared to 86.8% in 2009. The increase was due to the company streamlining manufacturing processes and becoming energy efficient. The Company also posted an adjusted EBITDA of $15.0 million, a 52% increase from $9.9 million from 2009. In these tough economic times, it's always good to see companies reducing debt, and Cyberonics…

MondayJun 07, 2010 8:45 am

Ecosphere Technologies, Inc. (ESPH.OB) to Deploy Ozonix Systems to the Gulf

Diversified environmental services company, Ecosphere Technologies, Inc. announced Friday that the company will participate in remediation efforts related to the BP oil spill; the announcement followed a Letter of Intent between Mid-Gulf Recovery Services, LLC and the company's majority owned subsidiary Ecosphere Energy Services, LLC. Ecosphere’s newest products will be deployed to the Gulf region, including the Ecosphere Ozonix Systems. The patented technology is a non-chemical water treatment system specifically built for removing oil and chemicals from water. John Kuelbs, Chairman of Ecosphere Energy Services, stated, "We look forward to working with Mid-Gulf Recovery Services to assist the people in…

MondayJun 07, 2010 8:38 am

Anthera Pharmaceuticals, Inc. (ANTH) Announces Dr. Colin Hislop as Chief Medical Officer

Anthera Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, recently announced that Colin Hislop, M.D. has been promoted to chief medical officer. Dr. Hislop replaces James E. Pennington, M.D., who will continue to serve as the company’s senior clinical fellow. Dr. Hislop has more than 15 years of drug development expertise in various areas, including cardiovascular‚ endocrinology‚ allergy/asthma and infectious disease. Prior to joining Anthera Pharmaceuticals‚ Dr. Hislop served as the vice president of clinical development for Peninsula Pharmaceuticals‚ Inc. where he oversaw three global development programs for Peninsula's anti-infective…

MondayJun 07, 2010 8:34 am

Genta Inc. (GETA.OB) Announces Combined Data of Early Endpoints from Phase 3 Trials of Genasense® in Advanced Melanoma

Yesterday, Genta Inc. announced the presentation of pooled results on early endpoints from their randomized Phase 3 trials of Genasense® (oblimersen sodium) Injection plus chemotherapy in patients with advanced melanoma. The Company presented the data yesterday at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The presentation included a "pooled analysis." This analysis assessed combined efficacy results for the endpoints of overall response and progression-free survival from both studies. Yesterday's presentation featured exploratory analyses using combined data on the early endpoints that are currently available, using both the intent-to-treat (ITT) populations (all patients…

MondayJun 07, 2010 8:30 am

Blyth, Inc. (BTH) Reports Higher First Quarter Earnings But Lowers Full Year Guidance

Blyth, Inc. reported net income of $4.5 million, or $0.51 per diluted share, in the first quarter of 2010 ending 4/30/2010. The company earned net income of $2.4 million, or $0.27 per diluted share, in the first quarter of 2009. Blyth, Inc. reported that revenues fell by 6% on a year over year basis, from $214.7 million in the first quarter of 2009 to $201.5 million in the quarter that just ended. The company said that on a local currency basis, revenues fell by 10%. Blyth, Inc. said that the proportion of international revenues reached 49% of total revenues in…

MondayJun 07, 2010 8:24 am

Vivakor, Inc. (VIVK.OB) Video Chart for Monday, June 7, 2010

VIVK is on radar now as a possible reversal play. The last two days have formed a bullish harami pattern with an increase in volume. Please click the following link: http://www.qualitystocks.net/videocharts.php?chartvid_id=412 Let us hear your thoughts below:

MondayJun 07, 2010 7:38 am

Cellceutix Corp. (CTIX.OB) Expedites Autism Studies in Response to Public Support; Announces Completion of Two Required Safety Pharmacology Studies

Cellceutix Corp. was pleased to announce this morning its acknowledgement of the many emails, phone calls and letters received regarding KM-391, its novel compound for the treatment of autism. In response to the outcries, Cellceutix has drawn upon its many resources and expedited scheduling of additional pre-clinical studies of the compound with the results to be released in upcoming weeks. Cellceutix worked with the world-renowned InterEd Faculty of Clinical Research (IFCR) in India to move rapidly in the development of KM-391. The Company's President and Chief Scientific Officer, Dr. Krishna Menon, as Chancellor of IFCR, was able to request expedited…

FridayJun 04, 2010 4:19 pm

Cherokee Inc. (CHKE) Reports 2010 First Quarter Net Income

Cherokee Inc. reported net income of $2.9 million, or $0.33 per diluted share, in the first quarter of 2010. The company earned $3.8 million, or $0.43 per diluted share, in the corresponding quarter in 2009. Cherokee Inc. said that royalty revenues also fell on a year over year basis, from $8.9 million in the first quarter of 2009 to $8.2 million in the quarter that just ended. The management of Cherokee Inc. said that the lower net income in the first quarter of 2010 relative to last year’s first quarter was caused by a lower than expected effective tax rate…

Site Search

Company Search